Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductas
e inhibitors or statin therapy demonstrate an improvement in cardiovascular
end points and coronary stenosis. However, an improvement in cardiovascula
r end points and coronary stenosis is incompletely explained by the baselin
e or treated LDL cholesterol level. The beneficial effects of statins on cl
inical events may involve nonlipid mechanisms that modify endothelial funct
ion, smooth muscle cells, and monocyte-macrophage: vasomotor function, infl
ammatory responses, and plaque stability. Augmented bioactivity of NO by st
atin therapy either indirectly by its effect on lipoprotein Levels and prot
ection of LDL from oxidation, or directly by effects on NO synthesis and re
lease, might account for enhancement of endothelium-dependent vasodilation.
Recent experimental and animal studies have demonstrated that statins dose
-dependently decrease smooth muscle cells migration and proliferation, inde
pendently of their ability to reduce plasma cholesterol. Moreover, statins
are able to reduce the in vitro cholesterol accumulation in macrophages and
expression of matrix metalloproteinase, resulting in plaque stability. The
se effects of statins were completely prevented by the addition of mevalona
te and partially by all-trails farnesol and all-trans geranylgeraniol, conf
irming the specific role of isoprenoid metabolites, probably through prenyl
ated proteins, in regulating these cellular events. Statins have been shown
to prevent the activation of monocytes into macrophages, inhibit the produ
ction of pro-inflammatory cytokines, C-reactive protein, and cellular adhes
ion molecules. Statins decrease the adhesion of monocyte to endothelial cel
ls. Accordingly, statins exert their cardiovascular benefits through a dire
ct antiatherogenic properties in the arterial wall, beyond their effects on
plasma lipids. (C) 2000 Elsevier Science B.V. All rights reserved.